HKEX intensifies efforts to attract international biotechnology listings as institutional capital increasingly flows toward Asian markets. Following Insilico Medicine’s successful December debut, the exchange positions itself as premier destination for life sciences companies seeking public market access.
Source: FinanceAsia Read Full Story